NDC 16729-393 - amlodipine besylate and olmesartan medoxomil
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 16729-393
- Package NDCs from labels
- 16729-393-10, 16729-393-15, 16729-393-16, 16729-393-17
- Manufacturer
- Accord Healthcare Inc. | Intas Pharmaceuticals Limited
- Effective date
- 2019-08-14
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| POVIDONE K30 - Accord Healthcare Inc. | Intas Pharmaceuticals Limited | Accord Healthcare Inc. | Intas Pharmaceuticals Limited | 2019-08-14 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 16729-393-10 | amlodipine besylate and olmesartan medoxomil | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 2 | |
| 16729-393-15 | amlodipine besylate and olmesartan medoxomil | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 2 | |
| 16729-393-16 | amlodipine besylate and olmesartan medoxomil | 500 in 1 BOTTLE | TABLET, FILM COATED | 500 | 2 | |
| 16729-393-17 | amlodipine besylate and olmesartan medoxomil | 1000 in 1 BOTTLE | TABLET, FILM COATED | 1000 | 2 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TiZO2 | TITANIUM DIOXIDE, ZINC OXIDE | Fallien Cosmeceuticals, LTD. | 30468afc-9616-4765-b046-12e97a0a7827 | 2010-12-20 | Warnings | 15FIX9V2JP |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.